These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39030902)

  • 1. SCA44- and SCAR13-associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms.
    Wang Y; Muraleetharan A; Langiu M; Gregory KJ; Hellyer SD
    Br J Pharmacol; 2024 Nov; 181(22):4514-4530. PubMed ID: 39030902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology.
    Muraleetharan A; Wang Y; Rowe MC; Gould A; Gregory KJ; Hellyer SD
    Mol Pharmacol; 2023 Jun; 103(6):325-338. PubMed ID: 36921922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics.
    Cho HP; Garcia-Barrantes PM; Brogan JT; Hopkins CR; Niswender CM; Rodriguez AL; Venable DF; Morrison RD; Bubser M; Daniels JS; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Biol; 2014 Oct; 9(10):2334-46. PubMed ID: 25137254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.
    Gregory KJ; Noetzel MJ; Rook JM; Vinson PN; Stauffer SR; Rodriguez AL; Emmitte KA; Zhou Y; Chun AC; Felts AS; Chauder BA; Lindsley CW; Niswender CM; Conn PJ
    Mol Pharmacol; 2012 Nov; 82(5):860-75. PubMed ID: 22863693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.
    Gregory KJ; Nguyen ED; Reiff SD; Squire EF; Stauffer SR; Lindsley CW; Meiler J; Conn PJ
    Mol Pharmacol; 2013 May; 83(5):991-1006. PubMed ID: 23444015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.
    Sengmany K; Hellyer SD; Albold S; Wang T; Conn PJ; May LT; Christopoulos A; Leach K; Gregory KJ
    Neuropharmacology; 2019 May; 149():83-96. PubMed ID: 30763654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site.
    Hellyer SD; Sengmany K; Keller AN; Christopoulos A; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114013. PubMed ID: 32389635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.
    Notartomaso S; Zappulla C; Biagioni F; Cannella M; Bucci D; Mascio G; Scarselli P; Fazio F; Weisz F; Lionetto L; Simmaco M; Gradini R; Battaglia G; Signore M; Puliti A; Nicoletti F
    Mol Brain; 2013 Nov; 6():48. PubMed ID: 24252411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contribution of metabotropic glutamate receptor 5 common allosteric binding site residues to biased allosteric agonism.
    Sengmany K; Hellyer SD; Christopoulos A; Lapinsky DJ; Leach K; Gregory KJ
    Biochem Pharmacol; 2020 Jul; 177():114011. PubMed ID: 32380090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Selective" Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu
    Hellyer SD; Albold S; Wang T; Chen ANY; May LT; Leach K; Gregory KJ
    Mol Pharmacol; 2018 May; 93(5):504-514. PubMed ID: 29514854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
    Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
    Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular calcium modulates actions of orthosteric and allosteric ligands on metabotropic glutamate receptor 1α.
    Jiang JY; Nagaraju M; Meyer RC; Zhang L; Hamelberg D; Hall RA; Brown EM; Conn PJ; Yang JJ
    J Biol Chem; 2014 Jan; 289(3):1649-61. PubMed ID: 24280223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5.
    Arsova A; Møller TC; Vedel L; Hansen JL; Foster SR; Gregory KJ; Bräuner-Osborne H
    Mol Pharmacol; 2020 Jul; 98(1):49-60. PubMed ID: 32358164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1
    Bossi S; Musante I; Bonfiglio T; Bonifacino T; Emionite L; Cerminara M; Cervetto C; Marcoli M; Bonanno G; Ravazzolo R; Pittaluga A; Puliti A
    Neurobiol Dis; 2018 Jan; 109(Pt A):44-53. PubMed ID: 28982591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors.
    Fu TT; Tu G; Ping M; Zheng GX; Yang FY; Yang JY; Zhang Y; Yao XJ; Xue WW; Zhu F
    Acta Pharmacol Sin; 2021 Aug; 42(8):1354-1367. PubMed ID: 33122823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?
    Dravolina OA; Zvartau E; Danysz W; Bespalov AY
    Psychopharmacology (Berl); 2017 May; 234(9-10):1333-1345. PubMed ID: 28285325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.
    Werthmann RC; Tzouros M; Lamerz J; Augustin A; Fritzius T; Trovò L; Stawarski M; Raveh A; Diener C; Fischer C; Gassmann M; Lindemann L; Bettler B
    Neuropharmacology; 2021 Jun; 190():108426. PubMed ID: 33279506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.
    Garcia-Barrantes PM; Cho HP; Niswender CM; Byers FW; Locuson CW; Blobaum AL; Xiang Z; Rook JM; Conn PJ; Lindsley CW
    J Med Chem; 2015 Oct; 58(20):7959-71. PubMed ID: 26426481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.